Outlook Therapeutics (OTLK) Prices $5 Million Direct Offering

Outlook Therapeutics Inc. (OTLK) priced a registered direct offering to raise approximately $5 million on May 29, 2026. The biopharmaceutical company agreed to sell common shares and warrants to purchase additional shares at a combined offering price. The offering includes shares of common stock at a price per share and accompanying warrants, with closing expected on or about June 2, 2026. Proceeds will be used for working capital and general corporate purposes, including advancing its ophthalmic therapy programs. The company did not disclose the exact number of securities to be issued. The announcement comes as Outlook Therapeutics seeks to navigate regulatory milestones and commercialization efforts for its lead product candidate.